PHARMAC funding
July 30, 2014
PHARMAC is seeking feedback
on a proposal to change or remove
funding restrictions for various
pharmaceuticals from 01 Oct.
Special Authority and/or hospital
medicines list restrictions for
pharmaceuticals including bee and
wasp venom allergy treatments,
nicorandil, bicalutamide and
perhexiline maleate, are among the
proposed affected medications.
In order to widen funded access,
full subsidy for benzydamine
hydrochloride would be available
through prescription endorsement
in the community for patients with
oral mucositis resulting from cancer
treatment and access to insulin
pump and pump consumables
would be widened to include cystic
fibrosis-related diabetes, among
other proposed funding rule
amendments, PHARMAC said.
To read more, CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jul 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jul 14
